Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode the biotech jargon buried in Longeveron’s SEC documents? Clinical-stage companies like Longeveron Inc pack trial data, FDA designations, and manufacturing risks into hundreds of pages, making it hard to spot what moves the stock.
Our platform solves that problem. Stock Titan delivers AI-powered summaries that turn the Longeveron annual report 10-K simplified, each Longeveron quarterly earnings report 10-Q filing, and every Longeveron 8-K material events explained into plain-English insights. Need real-time alerts? We stream Longeveron Form 4 insider transactions real-time so you instantly track Longeveron executive stock transactions Form 4 and monitor sentiment inside the boardroom.
Here’s how investors use it:
- Compare R&D spend and cash runway across quarters with our Longeveron earnings report filing analysis.
- Spot shelf registrations or trial read-outs the moment they hit EDGAR via curated 8-K summaries.
- Review compensation grids in the latest Longeveron proxy statement executive compensation without scrolling through tables.
- Audit insider confidence with detailed logs of Longeveron insider trading Form 4 transactions.
Whether you’re understanding Longeveron SEC documents with AI for the first time or need a deeper dive into pipeline risk factors, Stock Titan covers every form—10-K, 10-Q, 8-K, S-1, S-3, and more—with real-time feeds and expert context. Longeveron SEC filings explained simply means you can focus on investment decisions, not document hunting.
Longeveron General Counsel and Secretary Paul T. Lehr reported significant insider transactions on June 23, 2025. The transactions involved:
- Acquisition of 163,043 restricted stock units (RSUs) that fully vested on the grant date
- Disposition of 64,158 shares at $1.15 per share through share withholding for tax obligations
- Following these transactions, Lehr holds 255,635 shares directly, including RSUs subject to future vesting
The Form 4 filing demonstrates substantial equity-based compensation for a key executive officer, with immediate vesting of the new RSU grant. The share withholding for tax purposes is a common practice for executive equity compensation arrangements. This insider activity provides insights into Longeveron's executive compensation structure and retention strategies.
FAQ
What is the current stock price of Longeveron (LGVN)?
What is the market cap of Longeveron (LGVN)?
What is the core focus of Longeveron Inc?
How does Longeveron generate its therapeutic products?
What conditions are targeted by Longeveron's investigational therapies?
What is Lomecel-B and how does it work?
What regulatory designations has Longeveron achieved?
How does Longeveron differentiate itself in the competitive biotech landscape?
Who can benefit from understanding Longeveron Inc's research?
What role do mesenchymal stem cells play in Longeveron's treatments?
